<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biomerica Inc — News on 6ix</title>
<link>https://6ix.com/company/biomerica-inc</link>
<description>Latest news and press releases for Biomerica Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 12:19:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biomerica-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354e6f78dffbe2df0e65c4.webp</url>
<title>Biomerica Inc</title>
<link>https://6ix.com/company/biomerica-inc</link>
</image>
<item>
<title>Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026</title>
<link>https://6ix.com/company/biomerica-inc/news/biomericas-infoodsr-ibs-data-accepted-for-presentation-at-digestive-disease-week-2026</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomericas-infoodsr-ibs-data-accepted-for-presentation-at-digestive-disease-week-2026</guid>
<pubDate>Wed, 29 Apr 2026 12:19:00 GMT</pubDate>
<description>Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world’s largest GI medical conference, May 2–5, 2026, in ChicagoIRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an abstract evaluating the real-world clinical effectiveness of its inFoods® IBS diagnostic-guided therapy has been accepted for poste</description>
</item>
<item>
<title>Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway</title>
<link>https://6ix.com/company/biomerica-inc/news/biomerica-announces-medicare-administrative-contractor-confirmation-of-individual-claim-review-for-infoodsr-ibs-opening-a-scalable-medicare-commercialization-pathway</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomerica-announces-medicare-administrative-contractor-confirmation-of-individual-claim-review-for-infoodsr-ibs-opening-a-scalable-medicare-commercialization-pathway</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate The Medicare</description>
</item>
<item>
<title>Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs</title>
<link>https://6ix.com/company/biomerica-inc/news/biomerica-launches-infoodsr-ibs-in-canada-through-partnerships-with-phoenix-airmid-biomedical-and-canalt-health-labs</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomerica-launches-infoodsr-ibs-in-canada-through-partnerships-with-phoenix-airmid-biomedical-and-canalt-health-labs</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>— Represents Biomerica’s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS</description>
</item>
<item>
<title>Biomerica Reports Third Quarter Fiscal 2026 Financial Results</title>
<link>https://6ix.com/company/biomerica-inc/news/biomerica-reports-third-quarter-fiscal-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomerica-reports-third-quarter-fiscal-2026-financial-results</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical</description>
</item>
<item>
<title>Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe</title>
<link>https://6ix.com/company/biomerica-inc/news/biomerica-receives-first-commercial-order-for-its-h-pylori-test-hp-detecttm-from-one-of-the-largest-clinical-laboratory-chains-in-europe</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomerica-receives-first-commercial-order-for-its-h-pylori-test-hp-detecttm-from-one-of-the-largest-clinical-laboratory-chains-in-europe</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory</description>
</item>
<item>
<title>Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain</title>
<link>https://6ix.com/company/biomerica-inc/news/biomerica-receives-mhra-registration-for-hpdetecttm-allowing-commercial-sales-in-great-britain-12</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomerica-receives-mhra-registration-for-hpdetecttm-allowing-commercial-sales-in-great-britain-12</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Registration marks the Company’s entry into the UK market, where H. pylori affects an estimated 45% of the population across Europe’s five largest countries</description>
</item>
<item>
<title>Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution</title>
<link>https://6ix.com/company/biomerica-inc/news/vietnam-approves-biomericas-ez-detecttm-for-nationwide-distribution</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/vietnam-approves-biomericas-ez-detecttm-for-nationwide-distribution</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>Approval Marks Biomerica’s Strategic Entry into Southeast Asia’s Rapidly Growing Healthcare MarketSimple, FDA-Cleared At-Home Test Detects an Early Warning</description>
</item>
<item>
<title>Biomerica Reports Second Quarter Fiscal 2026 Financial Results</title>
<link>https://6ix.com/company/biomerica-inc/news/biomerica-reports-second-quarter-fiscal-221700508</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomerica-reports-second-quarter-fiscal-221700508</guid>
<pubDate>Wed, 14 Jan 2026 22:17:00 GMT</pubDate>
<description>Operating Expenses Decline 4% Year-to-DateBalance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2026 ended November 30, 2025. Key Highlights: 1.Biomerica Expands Commercialization of inFoods® IBS Through Collaboration with Henry Schein During the secon</description>
</item>
<item>
<title>Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test</title>
<link>https://6ix.com/company/biomerica-inc/news/biomerica-announces-cms-medicare-payment-131900375</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomerica-announces-cms-medicare-payment-131900375</guid>
<pubDate>Tue, 23 Dec 2025 13:19:00 GMT</pubDate>
<description>CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure.The $300 rate will apply to claims approved and paid by Medicare with dates of service on or after January 1, 2026.Adults of Medicare age comprise over 20% of US adults and a substantial portion of patients with IBS symptoms, making Medicare a critical payer for inFoods® IBS. IRVINE, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:</description>
</item>
<item>
<title>Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio</title>
<link>https://6ix.com/company/biomerica-inc/news/egyptian-drug-authority-authorizes-biomerica-130800839</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/egyptian-drug-authority-authorizes-biomerica-130800839</guid>
<pubDate>Thu, 11 Dec 2025 13:08:00 GMT</pubDate>
<description>Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and H. pylori infection • Designed for early detection of conditions that are related to the most common cancers and chronic diseases • Rapid, easy-to-use, and cost-effective screening for mass and individual use IRVINE, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global p</description>
</item>
<item>
<title>Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS</title>
<link>https://6ix.com/company/biomerica-inc/news/biomerica-infoods-ibs-product-featured-131900282</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomerica-infoods-ibs-product-featured-131900282</guid>
<pubDate>Tue, 25 Nov 2025 13:19:00 GMT</pubDate>
<description>Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic solutions, is proud to announce that its inFoods® IBS diagnostic-guided therapy product is being featured in the Fall 2025 issue of Biotherapeutics Quarterly, a Henry Schein publication. The article, titled “Precision Me</description>
</item>
<item>
<title>Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand</title>
<link>https://6ix.com/company/biomerica-inc/news/biomerica-expands-contract-development-manufacturing-131900078</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomerica-expands-contract-development-manufacturing-131900078</guid>
<pubDate>Thu, 06 Nov 2025 13:19:00 GMT</pubDate>
<description>Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service ExpansionComprehensive CDMO services now featured on Biomerica’s updated website IRVINE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic solutions, today announced the expansion of its Contract Development and Manufacturing Organization (CDMO) services to meet accelerating market demand. The Company is enhancing its capabilities to p</description>
</item>
<item>
<title>Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.</title>
<link>https://6ix.com/company/biomerica-inc/news/henry-schein-biomerica-enter-marketing-121900191</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/henry-schein-biomerica-enter-marketing-121900191</guid>
<pubDate>Thu, 16 Oct 2025 12:19:00 GMT</pubDate>
<description>- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization Strategy IRVINE, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practit</description>
</item>
<item>
<title>Biomerica Reports First Quarter Fiscal 2026 Financial Results</title>
<link>https://6ix.com/company/biomerica-inc/news/biomerica-reports-first-quarter-fiscal-132700299</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomerica-reports-first-quarter-fiscal-132700299</guid>
<pubDate>Wed, 15 Oct 2025 13:27:00 GMT</pubDate>
<description>Reported Improved Gross Margin from Contribution from Higher-Margin Product MixOperating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company’s Ongoing Focus on Cost Reduction and Operational EfficiencyEarnings per Share $0.00, Compared to a Net Loss of $0.08 per Share in the First Quarter of the Prior Fiscal Year. IRVINE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), ("Biomerica" or the "Company") a global provi</description>
</item>
<item>
<title>Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors</title>
<link>https://6ix.com/company/biomerica-inc/news/gary-huff-former-ceo-labcorp-121900391</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/gary-huff-former-ceo-labcorp-121900391</guid>
<pubDate>Wed, 08 Oct 2025 12:19:00 GMT</pubDate>
<description>Brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, and sales growth Extensive track record in commercializing advanced laboratory testing and insurer strategies IRVINE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic solutions, today announced the appointment of Gary Huff to its Board of Directors as an independent board member. Mr. Huff brings decades of leadership experience in the diagnost</description>
</item>
<item>
<title>Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes</title>
<link>https://6ix.com/company/biomerica-inc/news/biomerica-launches-ai-backed-infoods-120800393</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomerica-launches-ai-backed-infoods-120800393</guid>
<pubDate>Tue, 09 Sep 2025 12:08:00 GMT</pubDate>
<description>New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigger foods identified by inFoods® IBS testingIBS affects an estimated 40 million adults in the U.S. and hundreds of millions worldwide IRVINE, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic and therapeutic solutions, today announced the launch of its inFoods® IBS Trigger Food Navigator, a comprehensive AI-backed digital companion t</description>
</item>
<item>
<title>United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use</title>
<link>https://6ix.com/company/biomerica-inc/news/united-arab-emirates-ministry-health-121900962</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/united-arab-emirates-ministry-health-121900962</guid>
<pubDate>Wed, 03 Sep 2025 12:19:00 GMT</pubDate>
<description>10-minute home test detects early kidney damage in diabetic and hypertensive patientsHypertension affects roughly one-third of adults in the UAEDiabetes impacts approximately one in four UAE nationals IRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced today announced that the United Arab Emirates (UAE) Ministry of Health and Prevention has approved its Fortel® Kidney Test for home use. This important re</description>
</item>
<item>
<title>Biomerica Reports Fiscal 2025 Year End Results</title>
<link>https://6ix.com/company/biomerica-inc/news/biomerica-reports-fiscal-2025-end-211200198</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/biomerica-reports-fiscal-2025-end-211200198</guid>
<pubDate>Fri, 29 Aug 2025 21:12:00 GMT</pubDate>
<description>$1.3 Million in Operating Expense Reductions Achieved– Operating Loss Improves 19% Year-Over-YearResilient Portfolio Performance with International Sales Despite Global Economic UncertaintiesCash Used in Operating Activities Reduced to $3.8 Million vs. $5.3 Million in the Prior Year, Reflecting Stronger Operating Discipline IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2025 (Fiscal 2025). Th</description>
</item>
<item>
<title>United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use</title>
<link>https://6ix.com/company/biomerica-inc/news/united-arab-emirates-ministry-health-121900108</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/united-arab-emirates-ministry-health-121900108</guid>
<pubDate>Thu, 14 Aug 2025 12:19:00 GMT</pubDate>
<description>10-minute home test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerH. pylori linked to approximately 80% of gastric cancer cases; classified as a Class 1 carcinogen by the World Health OrganizationGastric cancer ranks as the fifth most common cancer globally and the fourth leading cause of cancer-related deaths IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic soluti</description>
</item>
<item>
<title>InFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code</title>
<link>https://6ix.com/company/biomerica-inc/news/infoods-ibs-receives-cpt-proprietary-120800871</link>
<guid isPermaLink="true">https://6ix.com/company/biomerica-inc/news/infoods-ibs-receives-cpt-proprietary-120800871</guid>
<pubDate>Wed, 02 Jul 2025 12:08:00 GMT</pubDate>
<description>PLA Code issuance by the American Medical Association CPT editorial panel marks a meaningful step toward attaining health insurance reimbursement and expanded patient access for inFoods® IBSinFoods® IBS provides personalized identification of food triggers to substantially improve IBS-related symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company focused on innovative gastroe</description>
</item>
</channel>
</rss>